Pauline Trémeaux1, Sébastien Lhomme2, Florence Abravanel2, Stéphanie Raymond2, Catherine Mengelle3, Jean-Michel Mansuy3, Jacques Izopet2. 1. Department of Virology, CHU Purpan, Toulouse, France. Electronic address: tremeaux.p@chu-toulouse.fr. 2. Department of Virology, CHU Purpan, Toulouse, France; INSERM UMR1043/CNRS UMR5282, Center for Pathophysiology of Toulouse Purpan, France, Toulouse III University Paul Sabatier, Toulouse, France. 3. Department of Virology, CHU Purpan, Toulouse, France.
Abstract
BACKGROUND: The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which appeared in late 2019, has been limited by isolating infected individuals. However, identifying such individuals requires accurate diagnostic tools. OBJECTIVE: This study evaluates the capacity of the Aptima™ Transcription-Mediated Amplification (TMA) assay (Hologic® Panther System) to detect the virus in clinical samples. STUDY DESIGN: We compared the Aptima™ assay to two in-house real-time RT-PCR techniques, one running on the Panther Fusion™ module and the other on the MagNA Pure 96 and Light-Cycler 480 instruments. We included a total of 200 respiratory specimens: 100 tested prospectively and 100 retrospectively (25 -ve/75 +ve). RESULTS: The final Cohen's kappa coefficients were: κ = 0.978 between the Aptima™ and Panther Fusion™ assays, κ = 0.945 between the Aptima™ and MagNA/LC480 assays and κ = 0.956 between the MagNA/LC480 and Panther Fusion™ assays. CONCLUSION: These findings indicate that the Aptima™ SARS-CoV-2 TMA assay data agree well with those obtained with our routine methods and that this assay can be used to diagnose coronavirus disease 2019 (COVID-19).
BACKGROUND: The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which appeared in late 2019, has been limited by isolating infected individuals. However, identifying such individuals requires accurate diagnostic tools. OBJECTIVE: This study evaluates the capacity of the Aptima™ Transcription-Mediated Amplification (TMA) assay (Hologic® Panther System) to detect the virus in clinical samples. STUDY DESIGN: We compared the Aptima™ assay to two in-house real-time RT-PCR techniques, one running on the Panther Fusion™ module and the other on the MagNA Pure 96 and Light-Cycler 480 instruments. We included a total of 200 respiratory specimens: 100 tested prospectively and 100 retrospectively (25 -ve/75 +ve). RESULTS: The final Cohen's kappa coefficients were: κ = 0.978 between the Aptima™ and Panther Fusion™ assays, κ = 0.945 between the Aptima™ and MagNA/LC480 assays and κ = 0.956 between the MagNA/LC480 and Panther Fusion™ assays. CONCLUSION: These findings indicate that the Aptima™ SARS-CoV-2TMA assay data agree well with those obtained with our routine methods and that this assay can be used to diagnose coronavirus disease 2019 (COVID-19).
Authors: Blair Lawley; Jenny Grant; Rhodri Harfoot; Jackson M Treece; Robert Day; Leonor C Hernández; Jo-Ann L Stanton; James E Ussher; Miguel E Quiñones-Mateu Journal: Viruses Date: 2021-11-04 Impact factor: 5.048
Authors: Sascha Dierks; Oliver Bader; Julian Schwanbeck; Uwe Groß; Michael S Weig; Kemal Mese; Raimond Lugert; Wolfgang Bohne; Andreas Hahn; Nicolas Feltgen; Setare Torkieh; Fenja R Denker; Peer Lauermann; Marcus W Storch; Hagen Frickmann; Andreas Erich Zautner Journal: J Clin Med Date: 2021-05-29 Impact factor: 4.241